Advertisement
Advertisement
ENTA
Enanta Pharmaceuticals, Inc
14.03
USDSponsored
-0.50
-3.44%
May 13, 16:00 UTC -4
Closed
Pre-Market
14.09
+0.06
+0.39%
ENTA Earnings Reports
Positive Surprise Ratio
ENTA beat 27 of 41 last estimates.
66%
Next Report
Date of Next Report
Aug 10, 2026
Estimate for Q3 26 (Revenue/ EPS)
$17.60M
/-$0.48
Implied change from Q2 26 (Revenue/ EPS)
+2.57%
/+6.67%
Implied change from Q3 25 (Revenue/ EPS)
-3.89%
/-43.53%
Enanta Pharmaceuticals, Inc earnings per share and revenue
On May 11, 2026, ENTA reported earnings of -0.45 USD per share (EPS) for Q2 26, beating the estimate of -0.49 USD, resulting in a 9.60% surprise. Revenue reached 17.16 million, compared to an expected 17.43 million, with a -1.57% difference. The market reacted with a -6.02% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 6 analysts forecast an EPS of -0.48 USD, with revenue projected to reach 17.60 million USD, implying an increase of 6.67% EPS, and increase of 2.57% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kamada Ltd
Report Date
May 13, 2026 For Q1 26
Estimate
$0.11
Actual
$0.07
Surprise
-40.32%
Abeona Therapeutics Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+17.31%
Milestone Pharmaceuticals Inc. Common Shares
Report Date
May 13, 2026 For Q1 26
Estimate
$0.31
Actual
-$0.20
Surprise
-163.94%
Spero Therapeutics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Equillium, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.04
Actual
-$0.06
Surprise
-34.53%
Spruce Biosciences, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$8.99
Actual
-$8.94
Surprise
+0.58%
BeyondSpring Inc. Ordinary Shares
Report Date
May 13, 2026 For Q1 26
Estimate
-Actual
-$0.05
Surprise
-
Tango Therapeutics, Inc.
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.32
Surprise
-0.13%
Longeveron Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.19
Surprise
-12.89%
Bionano Genomics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.96
Actual
-$0.76
Surprise
+21.57%
FAQ
What were Enanta Pharmaceuticals, Inc's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Enanta Pharmaceuticals, Inc reported EPS of -$0.45, beating estimates by 9.6%, and revenue of $17.16M, -1.57% below expectations.
How did the market react to Enanta Pharmaceuticals, Inc's Q2 2026 earnings?
The stock price moved down -6.02%, changed from $15.46 before the earnings release to $14.53 the day after.
When is Enanta Pharmaceuticals, Inc expected to report next?
The next earning report is scheduled for Aug 10, 2026.
What are the forecasts for Enanta Pharmaceuticals, Inc's next earnings report?
Based on 6
analysts, Enanta Pharmaceuticals, Inc is expected to report EPS of -$0.48 and revenue of $17.60M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement